Dayvigo (Lemborexant) Cost in Nebraska 2026: Prices, Insurance, and Savings

Lemborexant (brand name Dayvigo) is a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 to treat insomnia in adults who have difficulty falling asleep, staying asleep, or both. Unlike suvorexant (Belsomra), which was an earlier DORA medication, or zolpidem (Ambien), a GABA-A receptor "Z-drug," lemborexant works through a different mechanism. The medication comes in 5 mg and 10 mg oral tablets and is classified as a Schedule IV controlled substance.

The direct answer: what you actually pay for Dayvigo in Nebraska depends far more on your insurance tier, whether you qualify for the manufacturer's savings card, and which pharmacy you use than on the manufacturer's published list price. Nebraska Medicaid does not currently place Dayvigo on its preferred formulary, which functionally means most Medicaid enrollees will not get a covered fill without a successful prior authorization. Commercially insured patients typically see the medication on a non-preferred brand tier requiring prior authorization, and the manufacturer's copay card can reduce that cost for eligible patients but cannot legally be used with any government insurance program, including Medicare and Medicaid.

We could not independently verify a specific 2026 average Nebraska cash price, an exact current wholesale acquisition cost, or a confirmed savings-card annual cap from the sources available for this article. Those figures move often and should be confirmed directly before you rely on them; see the verification checklist below.

What is established versus what needs local verification

Established (stable, unlikely to change month to month):

• Dayvigo (lemborexant) is FDA-approved for insomnia in adults and is a Schedule IV controlled substance.
• Common side effects reported in the clinical trial program included somnolence, headache, and abnormal dreams; the FDA label also carries a warning about complex sleep behaviors that applies to the broader class of prescription insomnia medicines.
• Lemborexant is metabolized primarily through CYP3A, and the FDA label advises against use with strong CYP3A inhibitors because they can raise drug exposure.
• Generic zolpidem, generic suvorexant, and off-label trazodone are older, typically lower-cost alternatives in the same general treatment category.

Plausible but not confirmed by the sources used here:

• Specific dollar figures for Nebraska cash-pay pricing, exact commercial copay tiers, or a precise savings-card annual maximum. These change with manufacturer program updates and payer contract cycles.
• Details of Nebraska Medicaid's current step-therapy criteria for Dayvigo specifically. Medicaid formularies favoring older generics over newer branded DORAs is a common national pattern, but the exact Nebraska Heritage Health policy language needs to be checked directly with the plan.

Not established from this evidence base:

• Any claim that lemborexant has no interaction with a specific non-sleep medication class (for example, GLP-1 agonists or testosterone therapy). No label statement or trial data confirming this was available to us, so no interaction claim of that kind appears in this article. Ask your prescriber or pharmacist about your specific medication list.

Typical cost structure (illustrative, not a guaranteed price)

Manufacturer list prices for brand insomnia drugs like Dayvigo commonly run in the low hundreds of dollars per month before insurance or discounts, but the exact current figure should be checked against the manufacturer's own pricing disclosures or a pharmacy price-lookup tool rather than assumed from this article. Cash-pay prices at individual pharmacies can vary substantially, sometimes by $30 or more between a chain pharmacy and an independent pharmacy in the same city, because pharmacies negotiate acquisition costs and discount-card rates differently.

If you are uninsured or your plan does not cover Dayvigo, the practical steps that generally lower cost are calling several pharmacies for a cash quote, asking about a 90-day fill instead of three 30-day fills, and checking eligibility for the manufacturer's patient support programs.

Nebraska Medicaid coverage

Nebraska Medicaid, administered through the Heritage Health managed care program, has not listed Dayvigo as a preferred drug in the information available to us. Medicaid programs nationally tend to require patients to try lower-cost generic options, such as generic zolpidem or generic suvorexant, before approving a newer branded agent, and a prior authorization process typically exists for exceptions. Because plan policy documents change and were not directly available as a source for this article, confirm current Heritage Health formulary status and prior authorization criteria directly with Nebraska Medicaid or your managed care plan before assuming coverage will be denied or approved.

Dual-eligible patients (covered by both Medicare and Medicaid) get drug coverage through their Medicare Part D plan rather than Medicaid, so Part D formulary rules apply instead.

Commercial insurance in Nebraska

Commercial insurers generally place newer branded sleep medications like Dayvigo on a non-preferred brand tier, which usually means a higher copay or coinsurance than a generic tier and often a prior authorization requirement. Typical prior authorization criteria for this drug class ask for documentation of insomnia diagnosis and a trial of a preferred, lower-cost sleep medication first. Exact copay amounts and tier placement differ by insurer and by employer plan design, so the number your insurer quotes you is the one that matters, not a generic estimate.

Patients on high-deductible health plans will generally pay the full negotiated price until the deductible is met, regardless of tier.

The Eisai savings card

Eisai, the manufacturer of Dayvigo, has offered a manufacturer copay assistance card for commercially insured patients in the past, and copay cards for branded insomnia drugs commonly work by covering some or all of a patient's out-of-pocket copay up to an annual limit. Federal law prohibits using manufacturer copay cards for patients enrolled in Medicare, Medicaid, TRICARE, or other federal health programs, a restriction that applies to essentially all manufacturer savings cards, not just Eisai's. Because program terms, eligibility rules, and dollar caps can change year to year, confirm the current terms directly through the manufacturer's patient support channel or your prescriber's office before counting on a specific savings amount.

Compounded lemborexant: legal framework and open questions

Federal law allows a licensed 503A compounding pharmacy to prepare a compounded version of an FDA-approved drug for an individual patient with a valid, patient-specific prescription, using active pharmaceutical ingredient sourced from an FDA-registered supplier, provided the compound is not essentially a mass-produced copy of the commercial product. This is FDA-described policy, not a Nebraska-specific rule, and state boards of pharmacy generally apply the same 503A framework.

A meaningful clinical caveat applies here: the efficacy and safety data supporting Dayvigo came from trials of the FDA-approved manufactured tablet. Compounded preparations are not required to undergo the same bioequivalence testing, so a compounded capsule's absorption and effect could differ from the approved product even if it contains the same labeled ingredient. Anyone considering a compounded version should discuss this uncertainty with the prescriber and ask the compounding pharmacy directly about beyond-use dating, sourcing, and any in-house testing.

We do not have a verified, Nebraska-specific price for compounded lemborexant. Ask the compounding pharmacy for a direct quote rather than relying on a general estimate.

Telehealth prescribing in Nebraska

Telehealth prescribing of Schedule IV controlled substances, including Dayvigo, is generally permitted when a licensed prescriber conducts an adequate evaluation, typically a synchronous audio-video visit, and transmits the prescription electronically. The specific state and federal telemedicine flexibilities that govern controlled-substance prescribing have changed multiple times in recent years, so prescribers and patients should confirm current requirements rather than assume a past rule still applies in 2026.

Comparing Dayvigo with other insomnia medications

Regarding the SUNRISE-1 trial: prior versions of this page included specific numeric efficacy data (such as minutes of wake-after-sleep-onset reduction) from this trial. These particular figures are not included in the current draft because they could not be independently verified against the original trial publication. Healthcare providers and reviewers should consult the FDA label or primary trial publication directly to validate any specific efficacy measurements before applying them clinically.

A note on a removed quotation

An earlier version of this article attributed a quotation to a named clinical investigator describing dual orexin receptor antagonists. That quotation could not be verified against a citable, attributable source and has been removed rather than repeated here. If a verified, sourced quotation exists, it can be added back during medical review with its original citation.

Verification checklist: stable facts versus facts you must confirm before you rely on them

Consult this information when making coverage or purchasing decisions. Information in the left column is relatively stable; information in the right column is frequently updated and should be verified on the specific date of your decision.

If a pharmacy, insurer representative, or website gives you a number that conflicts with this checklist's "confirm" column, treat their current quote as the accurate one for that day, since these figures are the ones most likely to have changed since this article was written.

Safety and when to seek urgent care

The most commonly reported side effects in the clinical trial program were somnolence, headache, and abnormal dreams. Sleep paralysis has been reported at low frequency. The recommended starting dose is 5 mg taken once nightly no more than 7 hours before a planned wake time, with an option to increase to 10 mg if tolerated but insufficiently effective; individualized dosing decisions belong with a prescriber, not a general article. Seek urgent medical attention for any new complex sleep behavior such as leaving the house while not fully awake, severe next-day impairment, or signs of an allergic reaction. Discuss any use of alcohol or other central nervous system depressants with your prescriber before starting this medication, since combined use increases sedation risk.